CVMP adopted by consensus positive opinions for type II variations applications for Meloxidyl (meloxicam) and Imrestor (pegbovigrastim) concerning quality-related changes.
The Committee also adopted by consensus a positive opinion for a type II variation application for Bravecto (fluralaner) to lower the minimum age of target animals.
The Committee was informed of the formal notification from Emdoka bvba of their decision to withdraw the application for an initial marketing authorisation for Tulatrixx. More information about this application and the current state of the scientific assessment at the time of the withdrawal, together with the withdrawal letter from the applicant will be published on the Agency’s website in due course.
The Committee adopted by consensus positive opinions for the renewal of the marketing authorisations for Novaquin and Upcard...
Full text at GMPnews.Net